Skip to main content
. Author manuscript; available in PMC: 2011 Aug 26.
Published in final edited form as: Neuron. 2010 Aug 26;67(4):575–587. doi: 10.1016/j.neuron.2010.07.019

Fig. 6. Reduction of VDAC1 levels accelerates disease onset and diminishes survival in the hSOD1G37R mouse model of ALS.

Fig. 6

Ages of (A) disease onset (determined as the time when mice reached peak body weight), (B) early disease (determined as the time when mice lost 10% of maximal weight) and (C) disease end stage (determined as the time when the animal could not right itself within 20 seconds when placed on its side) of SOD1G37R-VDAC1+/- (blue) and SOD1G37R-VDAC1+/+ littermates (red). Mean ages ± s.d. is provided. (D, E, F) Mean onset (D), mean duration of early disease (from onset to 10% weight loss; E) and mean duration of late disease (from 10% weight loss to end-stage; F). Error bars denote s.d. See also Fig. S1.